369 related articles for article (PubMed ID: 25287751)
1. Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.
Iepsen EW; Lundgren J; Dirksen C; Jensen JE; Pedersen O; Hansen T; Madsbad S; Holst JJ; Torekov SS
Int J Obes (Lond); 2015 May; 39(5):834-41. PubMed ID: 25287751
[TBL] [Abstract][Full Text] [Related]
2. GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.
Iepsen EW; Lundgren JR; Hartmann B; Pedersen O; Hansen T; Jørgensen NR; Jensen JE; Holst JJ; Madsbad S; Torekov SS
J Clin Endocrinol Metab; 2015 Aug; 100(8):2909-17. PubMed ID: 26043228
[TBL] [Abstract][Full Text] [Related]
3. Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial.
Jensen SBK; Sørensen V; Sandsdal RM; Lehmann EW; Lundgren JR; Juhl CR; Janus C; Ternhamar T; Stallknecht BM; Holst JJ; Jørgensen NR; Jensen JB; Madsbad S; Torekov SS
JAMA Netw Open; 2024 Jun; 7(6):e2416775. PubMed ID: 38916894
[TBL] [Abstract][Full Text] [Related]
4. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.
Silver HJ; Olson D; Mayfield D; Wright P; Nian H; Mashayekhi M; Koethe JR; Niswender KD; Luther JM; Brown NJ
Diabetes Obes Metab; 2023 Aug; 25(8):2340-2350. PubMed ID: 37188932
[TBL] [Abstract][Full Text] [Related]
5. Exposure-response analyses of liraglutide 3.0 mg for weight management.
Wilding JP; Overgaard RV; Jacobsen LV; Jensen CB; le Roux CW
Diabetes Obes Metab; 2016 May; 18(5):491-9. PubMed ID: 26833744
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
Siskind D; Hahn M; Correll CU; Fink-Jensen A; Russell AW; Bak N; Broberg BV; Larsen J; Ishøy PL; Vilsbøll T; Knop FK; Kisely S; Ebdrup BH
Diabetes Obes Metab; 2019 Feb; 21(2):293-302. PubMed ID: 30187620
[TBL] [Abstract][Full Text] [Related]
7. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
[TBL] [Abstract][Full Text] [Related]
8. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.
Ard J; Fitch A; Fruh S; Herman L
Adv Ther; 2021 Jun; 38(6):2821-2839. PubMed ID: 33977495
[TBL] [Abstract][Full Text] [Related]
9. Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet.
Jensen SBK; Lundgren JR; Janus C; Juhl CR; Olsen LM; Rosenkilde M; Holst JJ; Stallknecht BM; Madsbad S; Torekov SS
BMJ Open; 2019 Nov; 9(11):e031431. PubMed ID: 31678947
[TBL] [Abstract][Full Text] [Related]
10. Endocannabinoid-related molecules predict the metabolic efficacy of GLP-1 receptor agonism in humans with obesity.
Matias I; Lehmann EW; Zizzari P; Byberg S; Cota D; Torekov SS; Quarta C
J Endocrinol Invest; 2024 May; 47(5):1289-1294. PubMed ID: 37924474
[TBL] [Abstract][Full Text] [Related]
11. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
12. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP
Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054
[TBL] [Abstract][Full Text] [Related]
13. Effects of treatment with Glucagon-like peptide-1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta-analysis.
Wang W; Wei R; Huang Z; Luo J; Pan Q; Guo L
Diabetes Metab Res Rev; 2023 Oct; 39(7):e3680. PubMed ID: 37356073
[TBL] [Abstract][Full Text] [Related]
14. Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.
Brown JD; McAnally D; Ayala JE; Burmeister MA; Morfa C; Smith L; Ayala JE
Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R595-R608. PubMed ID: 29949410
[TBL] [Abstract][Full Text] [Related]
15. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile.
Larsen AT; Gydesen S; Sonne N; Karsdal MA; Henriksen K
BMC Endocr Disord; 2021 Jan; 21(1):10. PubMed ID: 33413317
[TBL] [Abstract][Full Text] [Related]
16. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.
Jensterle M; Pirš B; Goričar K; Dolžan V; Janež A
Eur J Clin Pharmacol; 2015 Jul; 71(7):817-24. PubMed ID: 25991051
[TBL] [Abstract][Full Text] [Related]
17. The effect of meal frequency in a reduced-energy regimen on the gastrointestinal and appetite hormones in patients with type 2 diabetes: A randomised crossover study.
Belinova L; Kahleova H; Malinska H; Topolcan O; Windrichova J; Oliyarnyk O; Kazdova L; Hill M; Pelikanova T
PLoS One; 2017; 12(4):e0174820. PubMed ID: 28369078
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: A narrative review.
Clemens KK; Ernst J; Khan T; Reichert S; Khan Q; LaPier H; Chiu M; Stranges S; Sahi G; Castrillon-Ramirez F; Moist L;
Nutr Metab Cardiovasc Dis; 2023 Jun; 33(6):1111-1120. PubMed ID: 37100640
[TBL] [Abstract][Full Text] [Related]
19. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.
Nørregaard PK; Deryabina MA; Tofteng Shelton P; Fog JU; Daugaard JR; Eriksson PO; Larsen LF; Jessen L
Diabetes Obes Metab; 2018 Jan; 20(1):60-68. PubMed ID: 28598027
[TBL] [Abstract][Full Text] [Related]
20. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(8):3-18. PubMed ID: 32740121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
